Discovery of WNT9B Gene Mutation Significantly Increases Prostate Cancer Risk
/in Observational/by MaxRethinking Treatment for mHSPC: Insights from Dr. Karim Fizazi
/in Expert Insights, Observational, Retrospective studies/by MaxRetrospective study: Real-World Effectiveness of Apalutamide in mHSPC
/in Observational, Retrospective studies/by MaxNew Blood Test Predicts Prognosis for Advanced Prostate Cancer Patients
/in Observational, Post-hoc/by MaxBone-Modifying Agents Linked to Improved Survival in Advanced Prostate Cancer
/in Observational, Retrospective studies/by MaxMatching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxRethinking the “Lower is Better” Approach to LDL-C: Examining the Relationship Between Low LDL-C and Prostate Cancer Risk in Non-Hypertensive Men
/in Observational, Retrospective studies/by MaxThe Role of HSD3B1 in Prostate Cancer Progression and Treatment
/in Observational, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 44/2026 November 1, 2026
- UPDATE: JNJ-6143 RIPTAC Advances to Randomized Phase 3 Trial With Overall Survival Endpoint October 31, 2026
- Phase 1/2 Trial Will Investigate STAR0602 Plus Nivolumab in Metastatic Prostate Cancer October 31, 2026
- TIDE-PC Phase 2 Trial Will Test Testosterone-Guided ADT De-Escalation in Metastatic Prostate Cancer October 31, 2026